TrialCardiovascular drugs and therapy2016

Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia.

Robert S Rosenson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.